about
Antiviral drugs for viruses other than human immunodeficiency virusAnalysis of inhibitor binding in influenza virus neuraminidaseZanamivir: from drug design to the clinicSafety and pharmacokinetics of intravenous zanamivir treatment in hospitalized adults with influenza: an open-label, multicenter, single-arm, phase II studyPregnancy outcome following maternal use of zanamivir or oseltamivir during the 2009 influenza A/H1N1 pandemic: a national prospective surveillance study.Antivirals for the treatment and prevention of epidemic and pandemic influenzaInfluenza and its treatment during pregnancy: A review.In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.Maternal deaths associated with H1N1 influenza virus infection in Turkey: a whole-of-population report.Optimizing knowledge of antiviral medications for prophylaxis and treatment of influenza during pregnancy.Detection of E119V and E119I mutations in influenza A (H3N2) viruses isolated from an immunocompromised patient: challenges in diagnosis of oseltamivir resistance.Spotlight on zanamivir in influenza.Influenza: current evidence and informed predictions.In vitro genotoxic perspective of Tamiflu.Oseltamivir and inhaled zanamivir as influenza prophylaxis in Thai health workers: a randomized, double-blind, placebo-controlled safety trial over 16 weeks.Occasional review: influenza in COPD: pathogenesis, prevention, and treatment.Zanamivir oral delivery: enhanced plasma and lung bioavailability in ratsSafety of neuraminidase inhibitors against novel influenza A (H1N1) in pregnant and breastfeeding women.Novel strategies for targeting innate immune responses to influenza.Influenza pharmacotherapy: present situation, strategies and hopes.A Review of Antiviral and Antifungal Use and Safety during Pregnancy.Zanamivir: an influenza virus neuraminidase inhibitor.Pandemic influenza and pregnant women.Current strategies for management of influenza in the elderly population.Pandemic influenza and pregnant women: summary of a meeting of experts.
P2860
Q24635330-66220557-7CC0-4C28-B918-C456A1A6FF19Q27630835-7D96926C-DB99-48C8-AE84-DB9A593B4E42Q28344586-85787B7A-4EAA-4C5A-A259-2BB8CA6EBCAEQ30353217-32103591-5FDE-4591-9978-450AFBCF22ADQ30359847-E9E0979F-8EE6-41FE-99AA-E920FDE0AAEAQ30377241-2F8682B1-62B9-4333-99C7-5F788CE05C82Q30384118-37FAB5C9-79B5-4FAB-AA04-B7D9F2B9F452Q30387420-3D6B3293-E32E-44A7-AB73-FC3B86E2B781Q30402747-82BAC7FC-2139-4B4D-B14F-DB1D26A703CCQ30406272-C2F1CA25-2779-4E20-B481-0B8651344D47Q33826384-090D1C9F-5A10-4CEA-9745-A2830DA608CDQ35627901-2CAEA6D3-B24F-4DD0-AD4F-2729122A1245Q35843644-13B2E02E-1A42-46C7-B902-8C5F4AB4CFA7Q36095570-737FCE82-DB83-4B89-81CE-DA2D5B6C436DQ36593645-9CE50219-F768-4C6D-A9FC-AA5442252F56Q37017233-59AEA7EB-FB66-4E5F-B6C2-1A32CB54BF9DQ37145564-C9274994-D3E6-4E30-B178-3F4C2BCAEF5CQ37247004-D00201B0-FBB6-486C-A934-EFEC3B586102Q37445698-D622FCDD-B347-4592-ABE3-BDE735C0D00EQ37857854-2C7453A0-731D-4C37-9956-DF37340119ACQ38823841-1249F18F-C1E8-4D33-A7EB-DF424E55DDE9Q40419399-41D6DC07-DEF1-44A2-97FB-99F5B1AD887EQ43103192-0975A36D-E3E3-47E3-B8D3-B7C271762BC4Q44119551-19DF3191-696E-41E9-9412-9902B874C27FQ51934178-EF8C5306-5794-4F45-8231-2E736434E61C
P2860
description
1999 nî lūn-bûn
@nan
1999 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Zanamivir: a review of clinical safety.
@ast
Zanamivir: a review of clinical safety.
@en
type
label
Zanamivir: a review of clinical safety.
@ast
Zanamivir: a review of clinical safety.
@en
prefLabel
Zanamivir: a review of clinical safety.
@ast
Zanamivir: a review of clinical safety.
@en
P2093
P1433
P1476
Zanamivir: a review of clinical safety.
@en
P2093
P304
P356
10.2165/00002018-199921040-00003
P577
1999-10-01T00:00:00Z
P6179
1043457639